Dysregulation of Anti-Inflammatory Annexin A1 Expression in Progressive Crohns Disease

Angela Sena, Irina Grishina, Anne Thai, Larissa Goulart, Monica Macal, Anne Fenton, Jay Li, Thomas P Prindiville, Sonia Maria Oliani, Satya Dandekar, Luiz Goulart, Sumathi Sankaran-Walters

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background:Development of inflammatory bowel disease (IBD) involves the interplay of environmental and genetic factors with the host immune system. Mechanisms contributing to immune dysregulation in IBD are not fully defined. Development of novel therapeutic strategies is focused on controlling aberrant immune response in IBD. Current IBD therapy utilizes a combination of immunomodulators and biologics to suppress pro-inflammatory effectors of IBD. However, the role of immunomodulatory factors such as annexin A1 (ANXA1) is not well understood. The goal of this study was to examine the association between ANXA1 and IBD, and the effects of anti-TNF-α, Infliximab (IFX), therapy on ANXA1 expression.Methods:ANXA1 and TNF-α transcript levels in PBMC were measured by RT PCR. Clinical follow up included the administration of serial ibdQs. ANXA1 expression in the gut mucosa was measured by IHC. Plasma ANXA1 levels were measured by ELISA.Results:We found that the reduction in ANXA1 protein levels in plasma coincided with a decrease in the ANXA1 mRNA expression in peripheral blood of IBD patients. ANXA1 expression is upregulated during IFX therapy in patients with a successful intervention but not in clinical non-responders. The IFX therapy also modified the cellular immune activation in the peripheral blood of IBD patients. Decreased expression of ANXA1 was detected in the colonic mucosa of IBD patients with incomplete resolution of inflammation during continuous therapy, which correlated with increased levels of TNF-α transcripts. Gut mucosal epithelial barrier disruption was evident by increased plasma bacterial 16S levels.Conclusion:Loss of ANXA1 expression may support inflammation during IBD and can serve as a biomarker of disease progression. Changes in ANXA1 levels may be predictive of therapeutic efficacy.

Original languageEnglish (US)
Article numbere76969
JournalPLoS One
Volume8
Issue number10
DOIs
StatePublished - Oct 10 2013

Fingerprint

Annexin A1
Annexins
Crohn disease
inflammatory bowel disease
Crohn Disease
Inflammatory Bowel Diseases
Anti-Inflammatory Agents
therapeutics
Plasmas
mucosa
Therapeutics
digestive system
inflammation
Mucous Membrane
Blood
immunomodulators
Inflammation
blood
Immune system
mononuclear leukocytes

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Dysregulation of Anti-Inflammatory Annexin A1 Expression in Progressive Crohns Disease. / Sena, Angela; Grishina, Irina; Thai, Anne; Goulart, Larissa; Macal, Monica; Fenton, Anne; Li, Jay; Prindiville, Thomas P; Oliani, Sonia Maria; Dandekar, Satya; Goulart, Luiz; Sankaran-Walters, Sumathi.

In: PLoS One, Vol. 8, No. 10, e76969, 10.10.2013.

Research output: Contribution to journalArticle

Sena, A, Grishina, I, Thai, A, Goulart, L, Macal, M, Fenton, A, Li, J, Prindiville, TP, Oliani, SM, Dandekar, S, Goulart, L & Sankaran-Walters, S 2013, 'Dysregulation of Anti-Inflammatory Annexin A1 Expression in Progressive Crohns Disease', PLoS One, vol. 8, no. 10, e76969. https://doi.org/10.1371/journal.pone.0076969
Sena A, Grishina I, Thai A, Goulart L, Macal M, Fenton A et al. Dysregulation of Anti-Inflammatory Annexin A1 Expression in Progressive Crohns Disease. PLoS One. 2013 Oct 10;8(10). e76969. https://doi.org/10.1371/journal.pone.0076969
Sena, Angela ; Grishina, Irina ; Thai, Anne ; Goulart, Larissa ; Macal, Monica ; Fenton, Anne ; Li, Jay ; Prindiville, Thomas P ; Oliani, Sonia Maria ; Dandekar, Satya ; Goulart, Luiz ; Sankaran-Walters, Sumathi. / Dysregulation of Anti-Inflammatory Annexin A1 Expression in Progressive Crohns Disease. In: PLoS One. 2013 ; Vol. 8, No. 10.
@article{24c7a441d49941d189b4b8978b344e9d,
title = "Dysregulation of Anti-Inflammatory Annexin A1 Expression in Progressive Crohns Disease",
abstract = "Background:Development of inflammatory bowel disease (IBD) involves the interplay of environmental and genetic factors with the host immune system. Mechanisms contributing to immune dysregulation in IBD are not fully defined. Development of novel therapeutic strategies is focused on controlling aberrant immune response in IBD. Current IBD therapy utilizes a combination of immunomodulators and biologics to suppress pro-inflammatory effectors of IBD. However, the role of immunomodulatory factors such as annexin A1 (ANXA1) is not well understood. The goal of this study was to examine the association between ANXA1 and IBD, and the effects of anti-TNF-α, Infliximab (IFX), therapy on ANXA1 expression.Methods:ANXA1 and TNF-α transcript levels in PBMC were measured by RT PCR. Clinical follow up included the administration of serial ibdQs. ANXA1 expression in the gut mucosa was measured by IHC. Plasma ANXA1 levels were measured by ELISA.Results:We found that the reduction in ANXA1 protein levels in plasma coincided with a decrease in the ANXA1 mRNA expression in peripheral blood of IBD patients. ANXA1 expression is upregulated during IFX therapy in patients with a successful intervention but not in clinical non-responders. The IFX therapy also modified the cellular immune activation in the peripheral blood of IBD patients. Decreased expression of ANXA1 was detected in the colonic mucosa of IBD patients with incomplete resolution of inflammation during continuous therapy, which correlated with increased levels of TNF-α transcripts. Gut mucosal epithelial barrier disruption was evident by increased plasma bacterial 16S levels.Conclusion:Loss of ANXA1 expression may support inflammation during IBD and can serve as a biomarker of disease progression. Changes in ANXA1 levels may be predictive of therapeutic efficacy.",
author = "Angela Sena and Irina Grishina and Anne Thai and Larissa Goulart and Monica Macal and Anne Fenton and Jay Li and Prindiville, {Thomas P} and Oliani, {Sonia Maria} and Satya Dandekar and Luiz Goulart and Sumathi Sankaran-Walters",
year = "2013",
month = "10",
day = "10",
doi = "10.1371/journal.pone.0076969",
language = "English (US)",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "10",

}

TY - JOUR

T1 - Dysregulation of Anti-Inflammatory Annexin A1 Expression in Progressive Crohns Disease

AU - Sena, Angela

AU - Grishina, Irina

AU - Thai, Anne

AU - Goulart, Larissa

AU - Macal, Monica

AU - Fenton, Anne

AU - Li, Jay

AU - Prindiville, Thomas P

AU - Oliani, Sonia Maria

AU - Dandekar, Satya

AU - Goulart, Luiz

AU - Sankaran-Walters, Sumathi

PY - 2013/10/10

Y1 - 2013/10/10

N2 - Background:Development of inflammatory bowel disease (IBD) involves the interplay of environmental and genetic factors with the host immune system. Mechanisms contributing to immune dysregulation in IBD are not fully defined. Development of novel therapeutic strategies is focused on controlling aberrant immune response in IBD. Current IBD therapy utilizes a combination of immunomodulators and biologics to suppress pro-inflammatory effectors of IBD. However, the role of immunomodulatory factors such as annexin A1 (ANXA1) is not well understood. The goal of this study was to examine the association between ANXA1 and IBD, and the effects of anti-TNF-α, Infliximab (IFX), therapy on ANXA1 expression.Methods:ANXA1 and TNF-α transcript levels in PBMC were measured by RT PCR. Clinical follow up included the administration of serial ibdQs. ANXA1 expression in the gut mucosa was measured by IHC. Plasma ANXA1 levels were measured by ELISA.Results:We found that the reduction in ANXA1 protein levels in plasma coincided with a decrease in the ANXA1 mRNA expression in peripheral blood of IBD patients. ANXA1 expression is upregulated during IFX therapy in patients with a successful intervention but not in clinical non-responders. The IFX therapy also modified the cellular immune activation in the peripheral blood of IBD patients. Decreased expression of ANXA1 was detected in the colonic mucosa of IBD patients with incomplete resolution of inflammation during continuous therapy, which correlated with increased levels of TNF-α transcripts. Gut mucosal epithelial barrier disruption was evident by increased plasma bacterial 16S levels.Conclusion:Loss of ANXA1 expression may support inflammation during IBD and can serve as a biomarker of disease progression. Changes in ANXA1 levels may be predictive of therapeutic efficacy.

AB - Background:Development of inflammatory bowel disease (IBD) involves the interplay of environmental and genetic factors with the host immune system. Mechanisms contributing to immune dysregulation in IBD are not fully defined. Development of novel therapeutic strategies is focused on controlling aberrant immune response in IBD. Current IBD therapy utilizes a combination of immunomodulators and biologics to suppress pro-inflammatory effectors of IBD. However, the role of immunomodulatory factors such as annexin A1 (ANXA1) is not well understood. The goal of this study was to examine the association between ANXA1 and IBD, and the effects of anti-TNF-α, Infliximab (IFX), therapy on ANXA1 expression.Methods:ANXA1 and TNF-α transcript levels in PBMC were measured by RT PCR. Clinical follow up included the administration of serial ibdQs. ANXA1 expression in the gut mucosa was measured by IHC. Plasma ANXA1 levels were measured by ELISA.Results:We found that the reduction in ANXA1 protein levels in plasma coincided with a decrease in the ANXA1 mRNA expression in peripheral blood of IBD patients. ANXA1 expression is upregulated during IFX therapy in patients with a successful intervention but not in clinical non-responders. The IFX therapy also modified the cellular immune activation in the peripheral blood of IBD patients. Decreased expression of ANXA1 was detected in the colonic mucosa of IBD patients with incomplete resolution of inflammation during continuous therapy, which correlated with increased levels of TNF-α transcripts. Gut mucosal epithelial barrier disruption was evident by increased plasma bacterial 16S levels.Conclusion:Loss of ANXA1 expression may support inflammation during IBD and can serve as a biomarker of disease progression. Changes in ANXA1 levels may be predictive of therapeutic efficacy.

UR - http://www.scopus.com/inward/record.url?scp=84885408176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885408176&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0076969

DO - 10.1371/journal.pone.0076969

M3 - Article

C2 - 24130820

AN - SCOPUS:84885408176

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 10

M1 - e76969

ER -